Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.
Drug distributor Cencora raised its annual adjusted profit forecast on Thursday.
Cencora (COR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora is a 'super cash cow' with high capital turnover and low margins, generating substantial free cash flow from its competitive advantages. COR's business model thrives on low-cost operations, ensuring resilience in both high and low pricing environments. Despite inflation risks, COR's negative net working capital and efficient capital allocation enhance its ability to grow and generate cash.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.